Our vision, aims, principles, science and impact. Tackling Infections to Benefit Africa (TIBA, which means “to cure an infection” in Swahili) is an Africa-led, wide-ranging, multi-disciplinary research programme that explores and draws lessons from the ways that different African health systems tackle infectious diseases. Through TIBA, the University of Edinburgh will be working in partnerships with researchers from Botswana, Ghana, Kenya, Rwanda, South Africa, Sudan, Tanzania, Uganda and Zimbabwe to generate new knowledge and inform comparative analyses of health systems. Our Vision To harness the expertise and technical capability in biomedical and social sciences at the University of Edinburgh (UoE) and African partners to reduce the burden and threat of infectious diseases in Africa by informing and influencing health policy and strengthening health systems.TIBA will help empower African scientists to effectively and sustainably tackle neglected tropical diseases (such as schistosomiasis, malaria, trypanosomiasis and lymphatic filariasis), and improve preparedness for epidemics (such as Ebola and Covid-19). TIBA Aims Improve the diagnosis and surveillance of infectious diseases in resource-poor settingsImprove the deployment of existing drug treatments and enhance local capacity to develop new onesImprove the deployment of existing vaccines and enhance local capacity to develop new onesImprove the management of endemic and epidemic infectious diseases by:Strengthening health systems, governance and ethicsImproving policy development and implementationEnhancing capacity to respond to infectious disease emergencies TIBA Principles Our work is Africa-ledWe seek to shift the centre of gravity for research for Africa to AfricaWe believe in equitable partnershipsWe strive for inclusive engagement, "we leave no one behind" Our science and impact Disciplines: infection biology, clinical medicine, primary health care, health systems, international development, governance and ethics, diagnostics, surveillance and epidemiology, molecular biology and drug development, immunology and vaccinology, genomics and bioinformatics, synthetic biology, innovation.Diseases: schistosomiasis, malaria, trypanosomiasis, lymphatic filariasis, co-morbidities, NCDs + emerging infectious diseases. Partner countries population total ~ 300M Population living in poverty ~ 75M Health care spend (public funds) ~ US$20B TIBA beneficiaries ~ 50M people Achieved by: improving health policy, health systems operation and health R&D environmentin Africa partner countries and beyond Download the TIBA brochure This article was published on Friday 6 November 2026